Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170539 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD11B1NPSR1CA1CA2 | |
| SCHEMBL4170532 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD11B1NPSR1CA1CA2 | |
| SCHEMBL4177482 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD11B1NPSR1SOAT1LMNA | |
| SCHEMBL4177488 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD11B1NPSR1SOAT1LMNA | |
| SCHEMBL4177493 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD11B1NPSR1SOAT1LMNA | |
| SCHEMBL4177495 | 0.80 | HSD11B1 (0.45) | SMN1; SMN2HSD11B1NPSR1SOAT1KMT2A | |
| SCHEMBL4177483 | 0.80 | HSD11B1 (0.45) | SMN1; SMN2HSD11B1NPSR1SOAT1KMT2A | |
| SCHEMBL4177490 | 0.80 | HSD11B1 (0.45) | SMN1; SMN2HSD11B1NPSR1SOAT1KMT2A | |
| SCHEMBL6968887 | 0.78 | GFER (0.47) | SMN1; SMN2HSD11B1NPSR1CA1CA2 | |
| SCHEMBL8306745 | 0.78 | GFER (0.47) | SMN1; SMN2HSD11B1NPSR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | SMN1; SMN2 1918/4885HSD11B1 1690/4885NPSR1 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.